FEZ1 antibody (Biotin)

Catalog No. ABIN1404289

This Rabbit Polyclonal antibody specifically detects FEZ1 in WB and IHC (p). It exhibits reactivity toward Human, Rat and Mouse.

Quick Overview for FEZ1 antibody (Biotin) (ABIN1404289)

Target: FEZ1 (Fasciculation and Elongation Protein zeta 1 (Zygin I) (FEZ1))

Reactivity: Human, Rat, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FEZ1 antibody is conjugated to Biotin

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-FEZ1 Antibody (Biotin)

Cross-Reactivity: Human, Mouse, Rat

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human FEZ1

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
IHC-P 1:200-400

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C for 12 months.

Expiry Date: 12 months

Target Details for FEZ1

Target: FEZ1 (Fasciculation and Elongation Protein zeta 1 (Zygin I) (FEZ1))

Alternative Name: FEZ1

Background:

Synonyms: Fasciculation and elongation protein zeta 1, Fasciculation and elongation protein zeta-1, Fez 1, Fez, Fez-like zinc finger protein, FEZ1, FEZ1_HUMAN, Fezl, Forebrain embryonic zinc-finger like protein, Zpf312, Zygin 1, Zygin I, Zygin-1, Zygin1, ZyginI.

Background: Frequent loss of heterozygosity (LOH) at human chromosome 8p22-p21 is associated with various tumors including prostate and breast cancer. The 8p22-p21 region contains the FEZ1 gene, which is altered in tumors of the esophagus, prostate and breast. The FEZ1 protein (also known as leucine zipper putative tumor suppressor or LZTS1) contains a DNA-binding leucine zipper motif. FEZ1 is expressed in normal breast and prostate, but alterations in FEZ1 expression result in abnormal cell growth. The absence of FEZ1 expression is characteristic of breast and prostate cancer cell lines as well as primary breast and pro-state tumors. This absence of FEZ1 may be due to several factors, including mutations in the FEZ1 gene or hypermethylation of the CpG island flanking the FEZ1 promoter region. FEZ1 acts as a negative regulator of cell growth. During cell-cycle progression, FEZ1 localizes to microtubule components and is hyperphosphorylated by cAMP-dependent kinase.

Gene ID: 9638